P3 Health Partners Inc (PIII) Stock Analysis

AI analysis of P3 Health Partners Inc (PIII)

Buy

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

Valuation Metrics

The current forward P/E ratio for P3 Health Partners Inc (PIII) is 0.00, compared to its 5-year average forward P/E of -3.14.

Forward P/E

Fair

5Y Average P/E

-3.14

Current P/E

0.00

Overvalued

3.05

Undervalued

-9.34

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-2.05

Current EV/EBITDA

3.35

Overvalued

90.93

Undervalued

-95.03

Forward P/S

Strongly Overvalued

5Y Average P/S

0.13

Current P/S

0.46

Overvalued

0.24

Undervalued

0.02

Alphio AI Price Scenarios for PIII

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PIII

$8.18

Scenario price

B

Base

Base · 50%PIII

$7.60

Scenario price

B

Bear

Bear · 25%PIII

$6.61

Scenario price

PIII FAQ — answered by Alphio AI

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.